FI960556L - Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä - Google Patents

Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä Download PDF

Info

Publication number
FI960556L
FI960556L FI960556A FI960556A FI960556L FI 960556 L FI960556 L FI 960556L FI 960556 A FI960556 A FI 960556A FI 960556 A FI960556 A FI 960556A FI 960556 L FI960556 L FI 960556L
Authority
FI
Finland
Prior art keywords
delivery system
active pharmaceutical
pharmaceutical ingredients
flow delivery
transdermal slow
Prior art date
Application number
FI960556A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI960556A7 (fi
FI960556A0 (fi
Inventor
Eric J Roos
Chia-Ming Chiang
Tsung-Min Hsu
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22300358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI960556(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of FI960556A0 publication Critical patent/FI960556A0/fi
Publication of FI960556A7 publication Critical patent/FI960556A7/fi
Publication of FI960556L publication Critical patent/FI960556L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI960556A 1993-08-09 1994-08-05 Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä FI960556L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/104,414 US5554381A (en) 1993-08-09 1993-08-09 Low flux matrix system for delivering potent drugs transdermally
PCT/US1994/008883 WO1995004554A1 (en) 1993-08-09 1994-08-05 Low flux transdermal potent drug delivery system

Publications (3)

Publication Number Publication Date
FI960556A0 FI960556A0 (fi) 1996-02-07
FI960556A7 FI960556A7 (fi) 1996-03-11
FI960556L true FI960556L (fi) 1996-03-11

Family

ID=22300358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960556A FI960556L (fi) 1993-08-09 1994-08-05 Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä

Country Status (13)

Country Link
US (1) US5554381A (de)
EP (1) EP0716615B2 (de)
JP (1) JPH09505554A (de)
AT (1) ATE309004T1 (de)
AU (1) AU679557B2 (de)
CA (1) CA2169164A1 (de)
DE (1) DE69434537T3 (de)
DK (1) DK0716615T4 (de)
ES (1) ES2249763T5 (de)
FI (1) FI960556L (de)
NO (1) NO960487L (de)
NZ (1) NZ271797A (de)
WO (1) WO1995004554A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
AU2746397A (en) * 1996-04-30 1997-11-19 Theratech, Inc. Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19830651A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE02715112T1 (de) * 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
KR101144026B1 (ko) 2002-08-09 2012-05-09 후소 야쿠힝 고교 가부시끼가이샤 여성 호르몬 함유 부착제
AU2003301576A1 (en) 2002-10-22 2004-05-13 Eisai Co., Ltd. Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4914826B2 (ja) * 2005-02-28 2012-04-11 久光製薬株式会社 経皮吸収製剤
US8287923B2 (en) * 2005-06-10 2012-10-16 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8734413B2 (en) 2007-08-03 2014-05-27 Kimberly-Clark Worldwide, Inc. Packaged body adhering absorbent article
US7947027B2 (en) 2007-12-28 2011-05-24 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US8672911B2 (en) 2007-08-03 2014-03-18 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
EP2258396B1 (de) 2008-03-03 2017-09-06 Hisamitsu Pharmaceutical Co., Inc. Transdermal absorbierbares präparat
US11147722B2 (en) * 2008-11-10 2021-10-19 Kimberly-Clark Worldwide, Inc. Absorbent article with a multifunctional acrylate skin-adhesive composition
US10022468B2 (en) 2009-02-02 2018-07-17 Kimberly-Clark Worldwide, Inc. Absorbent articles containing a multifunctional gel
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
US9364487B2 (en) * 2011-11-04 2016-06-14 Agile Therapeutics, Inc. Dermal delivery compositions and methods
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (de) 2013-08-22 2020-01-08 The General Hospital Corporation Hemmer der humanen 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
EP3303286B1 (de) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
KR102123365B1 (ko) 2015-07-28 2020-06-16 바이옴 테라퓨틱스 리미티드 항박테리아 치료제 및 예방제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.

Also Published As

Publication number Publication date
AU7556294A (en) 1995-02-28
ATE309004T1 (de) 2005-11-15
JPH09505554A (ja) 1997-06-03
EP0716615B1 (de) 2005-11-09
EP0716615A4 (de) 1997-06-11
NZ271797A (en) 1997-12-19
EP0716615A1 (de) 1996-06-19
CA2169164A1 (en) 1995-02-16
DE69434537T2 (de) 2006-07-20
NO960487D0 (no) 1996-02-06
US5554381A (en) 1996-09-10
DE69434537D1 (de) 2005-12-15
FI960556A7 (fi) 1996-03-11
NO960487L (no) 1996-02-06
DK0716615T4 (da) 2009-12-14
FI960556A0 (fi) 1996-02-07
AU679557B2 (en) 1997-07-03
ES2249763T3 (es) 2006-04-01
DE69434537T3 (de) 2010-04-15
ES2249763T5 (es) 2010-02-01
WO1995004554A1 (en) 1995-02-16
EP0716615B2 (de) 2009-10-21
DK0716615T3 (da) 2006-02-20

Similar Documents

Publication Publication Date Title
FI960556A7 (fi) Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärje stelmä
FI960042L (fi) Farmaseuttisia valmisteita niukkaliukoisia aktiivisia aineita varten
AU4449789A (en) Delivery system for pharmaceutical or therapeutic actives
KR950703383A (ko) 초음파 경피약제전달 시스템(ultrasonic transdermal drug delivery system)
PL325774A1 (en) Drug delivery system for two or more active substances
ZA962536B (en) Pharmaceutical composition for transdermal administration.
IS4102A (is) Kerfi til að skammta lyfjafræðilega virk efni
ZA965866B (en) 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
ZA9610650B (en) 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
FI972542L (fi) Transdermaalijärjestelmä useamman aktiivisen aineen samanaikaista antamista varten
FI953533L (fi) Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
FI973320L (fi) Kiinteitä aktiiviainetta sisältäviä valmisteita
FI961437A7 (fi) Vaikuttavan aineen luovuttava systeemi
FI955907A7 (fi) Laite farmaseuttisten aineiden antamiseksi
FI961282L (fi) Transdermaalinen terapeuttinen systeemi, jossa on asetyylisalisyylihappo vaikuttavana aineena
FI930644A7 (fi) Menetelmä transdermaalisten lääkkeenantojärjestelmien valmistamiseksi
IL113793A0 (en) Transdermal delivery system for anti-epileptic drugs
FI903613A7 (fi) Luovutussysteemi aktiiviaineita varten
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
FI955730L (fi) Lääkeaineen jakamiskoostumus alfa-adeno-reseptoreita estäville aineille
FI932786L (fi) Vaikuttavaa ainetta luovuttava laite
FI970053A7 (fi) Transdermaalinen lääkeaineen antosysteemi
EP0408019A3 (en) Pharmaceutical active derivative delivery systems
SI0710103T1 (en) Pharmaceutical compositions for hardly soluble active substances

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: CYGNUS, INC.

FD Application lapsed